2021
DOI: 10.1111/jdv.17208
|View full text |Cite
|
Sign up to set email alerts
|

Low response of granulomatous cheilitis to currently established treatments

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 5 publications
0
0
0
Order By: Relevance
“…Granulomatous cheilitis is an exclusion diagnosis, and most cases remain isolated; however, it can be associated with systemic diseases such as Crohn disease (CD), sarcoidosis, or Melkersson-Rosenthal syndrome. Current treatment primarily involves topical or intralesional corticosteroids, with severe cases often requiring systemic agents such as biologics, with variable outcomes and frequent relapses . The evidenced role of the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway in granuloma formation has brought interest in using JAK inhibitors for granulomatous skin diseases; to our knowledge, their effectiveness in GC remains unexplored.…”
mentioning
confidence: 99%
“…Granulomatous cheilitis is an exclusion diagnosis, and most cases remain isolated; however, it can be associated with systemic diseases such as Crohn disease (CD), sarcoidosis, or Melkersson-Rosenthal syndrome. Current treatment primarily involves topical or intralesional corticosteroids, with severe cases often requiring systemic agents such as biologics, with variable outcomes and frequent relapses . The evidenced role of the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway in granuloma formation has brought interest in using JAK inhibitors for granulomatous skin diseases; to our knowledge, their effectiveness in GC remains unexplored.…”
mentioning
confidence: 99%